Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485621 | 0.97 | NAMPT (0.52) | NAMPTGRM1GRM4ROCK2ROCK1 | |
| SCHEMBL6576406 | 0.91 | NAMPT (0.46) | NAMPTGRM1GRM4ROCK2ROCK1 | |
| SCHEMBL25252633 | 0.89 | NAMPT (0.45) | NAMPTGRM1GRM4ROCK2ROCK1 | |
| SCHEMBL12256158 | 0.88 | NAMPT (0.53) | NAMPTGRM1GRM4ROCK2ROCK1 | |
| SCHEMBL12934351 | 0.86 | NAMPT (0.52) | NAMPTGRM1GRM4ROCK2ROCK1 | |
| SCHEMBL12256120 | 0.85 | NAMPT (0.51) | NAMPTGRM1GRM4ROCK2ROCK1 | |
| SCHEMBL30125632 | 0.84 | NAMPT (0.46) | NAMPTGRM1GRM4ROCK2ROCK1 | |
| SCHEMBL5331486 | 0.84 | NAMPT (0.46) | NAMPTGRM1GRM4ROCK2ROCK1 | |
| SCHEMBL5335787 | 0.84 | NAMPT (0.50) | NAMPTGRM1GRM4ROCK2ROCK1 | |
| SCHEMBL13682849 | 0.83 | NAMPT (0.52) | NAMPTGRM1GRM4ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368628-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | DESIGN THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250295632-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| WO-2025122764-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4539842-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4539839-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | DESIGN THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4522168-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119584961-A | Methods and compounds for modulating huntington's disease | 设计治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4504339-A2 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4460302-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-7863455-B2 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-01-04 | — | — | US | disclosed |
| US-7863455-B2 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-01-04 | — | — | US | disclosed |
| US-7863455-B2 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-01-04 | — | — | US | disclosed |
| US-20070172826-A1 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070172826-A1 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070172826-A1 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-07-26 | — | — | US | disclosed |
| WO-2007045096-A1 | OLIGOHETEROAROMATIC LUMINISCENT ASSEMBLIES AS HIGH-AFFINITY DNA SEQUENCE-DIRECTED LIGANDS | UNIVERSITY OF SASKATCHEWAN (CA) | 2007-04-26 | — | — | WO | disclosed |
| EP-1719777-A1 | ELECTROCHEMICALLY ACTIVE LIGAND FOR SEQUENCE-SPECIFIC DETECTION OF DOUBLE-STRANDED NUCLEIC ACID MOLECULE | Japan Science and Technology Agency (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172826-A1 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | POLRMT, POLM, POLI | NAMPT 1801/4885GRM1 1914/4885GRM4 2999/4885 |
| US-20250368628-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | CLN6, GATAD2B, MITF | NAMPT 1389/4885GRM1 3330/4885GRM4 3422/4885 |
| US-20250295632-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, CLN6, ATXN2L | NAMPT 1233/4885GRM1 1108/4885GRM4 1650/4885 |
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, ATXN2L, ATXN10 | NAMPT 2924/4885GRM1 1358/4885GRM4 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.